199 related articles for article (PubMed ID: 33340135)
1. Prolactinoma in childhood and adolescence-Tumour size at presentation predicts management strategy: Single centre series and a systematic review and meta-analysis.
Arya VB; Aylwin SJB; Hulse T; Ajzensztejn M; Kalitsi J; Kalogirou N; Bodi I; Thomas N; Hampton T; Kapoor RR; Buchanan CR
Clin Endocrinol (Oxf); 2021 Mar; 94(3):413-423. PubMed ID: 33340135
[TBL] [Abstract][Full Text] [Related]
2. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Endoscopic Transsphenoidal Resection for Prolactinoma: A Retrospective Multicenter Case-series.
Zandbergen IM; Huntoon KM; White TG; Bakker LEH; Verstegen MJT; Ghalib LM; van Furth WR; Pelsma ICM; Dehdashti AR; Biermasz NR; Prevedello DM
Arch Med Res; 2023 Dec; 54(8):102919. PubMed ID: 38040527
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis and drug therapy of prolactinoma.
Ciccarelli E; Camanni F
Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
[TBL] [Abstract][Full Text] [Related]
5. Surgical outcomes of medically failed prolactinomas: a systematic review and meta-analysis.
Yagnik KJ; Erickson D; Bancos I; Atkinson JLD; Choby G; Peris-Celda M; Van Gompel JJ
Pituitary; 2021 Dec; 24(6):978-988. PubMed ID: 34580821
[TBL] [Abstract][Full Text] [Related]
6. Macroprolactinoma with secondary resistance to dopamine agonists: a case report and review of the literature.
Tng EL; Teo AE; Aung AT
J Med Case Rep; 2023 Mar; 17(1):96. PubMed ID: 36927797
[TBL] [Abstract][Full Text] [Related]
7. Clinical, Hormonal, and Neuroradiological Characteristics and Therapeutic Outcomes of Prolactinomas in Children and Adolescents at a Single Center.
Yang A; Cho SY; Park H; Kim MS; Kong DS; Shin HJ; Jin DK
Front Endocrinol (Lausanne); 2020; 11():527. PubMed ID: 32849307
[No Abstract] [Full Text] [Related]
8. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia.
Colao A; Sarno AD; Cappabianca P; Briganti F; Pivonello R; Somma CD; Faggiano A; Biondi B; Lombardi G
Eur J Endocrinol; 2003 Mar; 148(3):325-31. PubMed ID: 12611613
[TBL] [Abstract][Full Text] [Related]
9. Giant prolactinomas: the therapeutic approach.
Moraes AB; Silva CM; Vieira Neto L; Gadelha MR
Clin Endocrinol (Oxf); 2013 Oct; 79(4):447-56. PubMed ID: 23662975
[TBL] [Abstract][Full Text] [Related]
10. The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type.
Bolko P; Jaskuła M; Waśko R; Wołuń M; Sowiński J
Pol Arch Med Wewn; 2003 May; 109(5):489-95. PubMed ID: 14768178
[TBL] [Abstract][Full Text] [Related]
11. Start low, go slowly - mental abnormalities in young prolactinoma patients under cabergoline therapy.
Brichta CM; Wurm M; Krebs A; Schwab KO; van der Werf-Grohmann N
J Pediatr Endocrinol Metab; 2019 Sep; 32(9):969-977. PubMed ID: 31323004
[TBL] [Abstract][Full Text] [Related]
12. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis.
Colao A; Vitale G; Cappabianca P; Briganti F; Ciccarelli A; De Rosa M; Zarrilli S; Lombardi G
J Clin Endocrinol Metab; 2004 Apr; 89(4):1704-11. PubMed ID: 15070934
[TBL] [Abstract][Full Text] [Related]
13. Management of prolactinomas in children and adolescents; which factors define the response to treatment?
Alikasifoglu A; Celik NB; Ozon ZA; Gonc EN; Kandemir N
Pituitary; 2022 Feb; 25(1):167-179. PubMed ID: 34518999
[TBL] [Abstract][Full Text] [Related]
14. Giant prolactinomas larger than 60 mm in size: a cohort of massive and aggressive prolactin-secreting pituitary adenomas.
Shimon I; Sosa E; Mendoza V; Greenman Y; Tirosh A; Espinosa E; Popovic V; Glezer A; Bronstein MD; Mercado M
Pituitary; 2016 Aug; 19(4):429-36. PubMed ID: 27138902
[TBL] [Abstract][Full Text] [Related]
15. Italian Guidelines for the Management of Prolactinomas.
Cozzi R; Simona Auriemma R; De Menis E; Esposito F; Ferrante E; Iatì G; Mazzatenta D; Poggi M; Rudà R; Tortora F; Cruciani F; Mitrova Z; Saulle R; Vecchi S; Basile M; Cappabianca P; Paoletta A; Papini E; Persichetti A; Samperi I; Scoppola A; Bozzao A; Caputo M; Doglietto F; Ferraù F; Lania AG; Laureti S; Lello S; Locatelli D; Maffei P; Minniti G; Peri A; Ruini C; Settanni F; Silvani A; Veronese N; Grimaldi F; Attanasio R
Endocr Metab Immune Disord Drug Targets; 2023; 23(12):1459-1479. PubMed ID: 37171003
[TBL] [Abstract][Full Text] [Related]
16. Treatment of macroprolactinoma with cabergoline: a study of 85 patients.
Ferrari CI; Abs R; Bevan JS; Brabant G; Ciccarelli E; Motta T; Mucci M; Muratori M; Musatti L; Verbessem G; Scanlon MF
Clin Endocrinol (Oxf); 1997 Apr; 46(4):409-13. PubMed ID: 9196602
[TBL] [Abstract][Full Text] [Related]
17. Giant prolactinomas: clinical manifestations and outcomes of 16 Arab cases.
Almalki MH; Buhary B; Alzahrani S; Alshahrani F; Alsherbeni S; Alhowsawi G; Aljohani N
Pituitary; 2015 Jun; 18(3):405-9. PubMed ID: 25062894
[TBL] [Abstract][Full Text] [Related]
18. Hyperprolactinemia: pathophysiology and management.
Verhelst J; Abs R
Treat Endocrinol; 2003; 2(1):23-32. PubMed ID: 15871552
[TBL] [Abstract][Full Text] [Related]
19. Prolactin ≤1 ng/mL predicts macroprolactinoma reduction after cabergoline therapy.
Kim D; Ku CR; Kim K; Jung H; Lee EJ
Eur J Endocrinol; 2020 Feb; 182(2):177-183. PubMed ID: 31770105
[TBL] [Abstract][Full Text] [Related]
20. Primary medical therapy of micro- and macroprolactinomas in men.
Pinzone JJ; Katznelson L; Danila DC; Pauler DK; Miller CS; Klibanski A
J Clin Endocrinol Metab; 2000 Sep; 85(9):3053-7. PubMed ID: 10999785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]